Last reviewed · How we verify
UCB0022
At a glance
| Generic name | UCB0022 |
|---|---|
| Also known as | Glovadalen |
| Sponsor | UCB Biopharma SRL |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants (PHASE1)
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease (PHASE2)
- A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants (PHASE1)
- A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UCB0022 CI brief — competitive landscape report
- UCB0022 updates RSS · CI watch RSS
- UCB Biopharma SRL portfolio CI